Ryan Marotta, Assistant Editor

Learn about the new products and expanded indications approved by the FDA in February 2017.

As pharmacists and pharmacy students continue to work toward provider status, senators and representatives of the recently sworn-in Congress have reintroduced a bill that would bring the pharmacy profession closer to its goal.

Review the new products and expanded indications approved by the FDA in January 2017.

Review the new products and expanded indications approved by the FDA in January 2017.

Learn about the new products and expanded indications approved by the FDA in January 2017.

Although individuals aged 65 years and older face a heighted chance of developing complications from acute respiratory infections, a recent study has indicated that use of vitamin D supplements can help these patients strengthen their immunity against such infections.

Xyzal, an antihistamine, was previously available only as a prescription medication.

Sanofi announced today that the FDA has approved its 24-hour formulation of levocetirizine dihydrochloride (Xyzal Allergy 24HR) for the over-the-counter (OTC) treatment of symptoms associated with seasonal and year-round allergies.

The FDA recently approved Endo International and Par Pharmaceutical’s new drug application for its 50 mg/ml ephedrine sulfate injection.

Officials with AstraZeneca recently announced that the FDA has expanded the indication of its 80/4.5 mcg budesonide and formoterol fumarate dihydrate inhalation aerosol (Symbicort), approving the drug for the treatment of asthma in patients aged 6 to 12 years.

Pharmacists have yet another reason to promote smoking cessation, as the results of a new study have indicated that smokers with depression can boost their mental health by kicking the habit.

Amidst recent efforts to dismantle the Affordable Care Act, a newly-released report has suggested that repealing several provisions of the health reform law could potentially raise premiums and leave millions of Americans without health insurance coverage.

NCPA emphasizes that a replacement for the Affordable Care Act must preserve prescription drug coverage to help reduce overall health care costs.

NCPA advises lawmakers to maintain provision that strengthens Medicare Part D medication therapy management programs.

As President-elect Donald Trump and congressional Republicans prepare their efforts to dismantle the Affordable Care Act, the NCPA has penned a letter to key representatives outlining its recommendations for future health care reform.

Learn about the new products and expanded indications approved by the FDA in December 2016.

Pharmacists have once more been ranked among the most honest and ethical professionals in the United States, according to the results of the latest Gallup poll on the topic.

Crisaborole ointment (Eucrisa) treats mild to moderate eczema in patients 2 years and older.

Phosphodiesterase 4 inhibitor is specifically indicated for the twice-daily treatment of atopic dermatitis.

The FDA has approved Anacor Pharmaceuticals’ crisaborole ointment (Eucrisa) for the treatment of mild to moderate eczema in patients 2 years and older.

Roche’s bevacizumab (Avastin) granted expanded indication for platinum-sensitive recurrent ovarian cancer.

Avastin was previously approved for the treatment of metastatic colorectal cancer, lung cancer, brain cancer, kidney cancer, and cervical cancer.

The FDA has expanded the indication of Roche’s bevacizumab (Avastin), allowing the drug to be used to treat several types of platinum-sensitive recurrent ovarian cancer.

Label expansion includes treatment of cardiovascular disease in adult patients with type 2 diabetes.

The FDA has approved a new indication for Boehringer Ingelheim’s empagliflozin (Jardiance), allowing it to be used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease.

Although the pharmacy profession has continued to evolve, the overall demand for pharmacists has waned since last year, according to the latest figures from the Aggregate Demand Index.

Pharmacy Times and Walmart honor students throughout the year with the Respect, Excellence, and Service in Pharmacy (RESPy) Award.

Learn about the new products and expanded indications approved by the FDA in October 2016.

Intrarosa is a once-daily vaginal insert for the treatment of moderate to severe pain during sexual intercourse as a result of menopause.